Who
Mark Chin
Director
Company insider
Files Form 4 as: Director, Disc Medicine; Director and 10% owner, Harpoon Therapeutics; Director, Iterum Therapeutics; Director and 10% owner, Enliven Therapeutics; Director and Other, Pyxis Oncology.
In numbers
- Trades disclosed
- 77
- Buys
- 6
- Sells
- 7
- Bought
- $26.7M
- Sold
- $11.0M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 24 May 2018
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,212 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,212 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 11 Mar 2024filed 11 Mar 2024 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code D | —2,033 | filing |
| 11 Mar 2024filed 11 Mar 2024 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code D | —1,016 | filing |
| 11 Mar 2024filed 11 Mar 2024 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code D | —3,214 | filing |
| 11 Mar 2024filed 11 Mar 2024 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code D | —2,300 | filing |
| 11 Mar 2024filed 11 Mar 2024 | Harpoon Therapeutics | SEC FORM 4 Code D | —13,224 | filing |
| 8 Mar 2024filed 11 Mar 2024 | Harpoon Therapeutics | SEC FORM 4 Code A | —424 at $0.00 | filing |
| 1 Jan 2024filed 3 Jan 2024 | Harpoon Therapeutics | SEC FORM 4 Code A | —1,072 at $0.00 | filing |
| 27 Nov 2023filed 28 Nov 2023 | Harpoon Therapeutics | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 1 Oct 2023filed 2 Oct 2023 | Harpoon Therapeutics | SEC FORM 4 Code A | —3,035 at $0.00 | filing |
| 1 Jul 2023filed 6 Jul 2023 | Harpoon Therapeutics | SEC FORM 4 Code A | —18,656 at $0.00 | filing |
| 22 Jun 2023filed 23 Jun 2023 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 15 Jun 2023filed 15 Jun 2023 | Iterum Therapeuticsoption or derivative | SEC FORM 4 Code M | —15,853 at $0.00 | filing |
| 15 Jun 2023filed 15 Jun 2023 | Iterum Therapeutics | SEC FORM 4 Code M | —15,853 at $0.00 | filing |
| 9 Jun 2023filed 9 Jun 2023 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,136 at $0.00 | filing |
| 1 Apr 2023filed 4 Apr 2023 | Harpoon Therapeutics | SEC FORM 4 Code A | —18,285 at $0.00 | filing |
| 29 Dec 2022filed 3 Jan 2023 | IRON Disc Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
News
Reception held in Mongolia to mark China's National Day - People's Daily Onlineen.people.cn · 23 Sep 2026Two Blockbuster Listings Mark China's Hard-tech Risestdaily.com · 11 Sep 2026Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst SaysELVN · dailypolitical.com · 21 Oct 2026Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearELVN · prnewswire.com · 14 Oct 2026Critical Analysis: Pyxis Oncology (NASDAQ:PYXS) versus Inovio Pharmaceuticals (NASDAQ:INO)PYXS · themarketsdaily.com · 8 Oct 2026
2 headlines in the last 90 days name Mark Chin; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.